Juan Burgos-Soto1, Eric Balestre, Albert Minga, Samuel Ajayi, Adrien Sawadogo, Marcel D Zannou, Valériane Leroy, Didier K Ekouevi, François Dabis, Renaud Becquet. 1. *Université de Bordeaux, ISPED, Centre INSERM U897-Epidémiologie-Biostatistique, Bordeaux, France; †INSERM, ISPED, Centre INSERM U897-Epidémiologie-Biostatistique, Bordeaux, France; ‡Centre Médical de Suivi de Donneurs de Sang (CMSDS), Abidjan, Côte d'Ivoire; §University of Abuja Teaching Hospital (UATH), Abuja, Nigeria; ‖Hôpital de jour, CHU Souro Sanou, Bobo Dioulasso, Burkina-Faso; ¶Centre de Prise en Charge des Personnes vivant avec le VIH, CHNU, Cotonou, Benin; and #Département des sciences fondamentales et santé publique, faculté des sciences de la santé, université de Lomé, Lomé, Togo.
Abstract
INTRODUCTION: This study aimed at estimating the incidence of pregnancy after antiretroviral therapy (ART) initiation in 8 West African countries over a 10-year period. METHODS: A retrospective analysis was conducted within the international database of the IeDEA West Africa Collaboration. All HIV-infected women aged <50 years and starting ART for their own health between 1998 and 2011 were eligible. Pregnancy after ART initiation was the main outcome and was based on clinical reporting. Poisson regression analysis accounting for country heterogeneity was computed to estimate first pregnancy incidence post-ART and to identify its associated factors. Pregnancy incidence rate ratios were adjusted on country, baseline CD4 count and clinical stage, hemoglobin, age, first ART regimen, and calendar year. RESULTS: Overall, 29,425 HIV-infected women aged 33 years in median (interquartile range, 28-38) contributed for 84,870 women-years of follow-up to this analysis. The crude incidence of first pregnancy (2304 events) was 2.9 per 100 women-years [95% confidence interval (CI): 2.7 to 3.0], the highest rate being reported among women aged 25-29 years: 4.7 per 100 women-years; 95% CI: 4.3 to 5.1. The overall Kaplan-Meier probability of pregnancy occurrence by the fourth year on ART was 10.9% (95% CI: 10.4 to 11.4) and as high as 28.4% (95% CI: 26.3 to 30.6) among women aged 20-29 years at ART initiation. CONCLUSIONS: The rate of pregnancy occurrence after ART initiation among HIV-infected women living in the West Africa region was high. Family planning services tailored to procreation needs should be provided to all HIV-infected women initiating ART and health consequences carefully monitored in this part of the world.
INTRODUCTION: This study aimed at estimating the incidence of pregnancy after antiretroviral therapy (ART) initiation in 8 West African countries over a 10-year period. METHODS: A retrospective analysis was conducted within the international database of the IeDEA West Africa Collaboration. All HIV-infectedwomen aged <50 years and starting ART for their own health between 1998 and 2011 were eligible. Pregnancy after ART initiation was the main outcome and was based on clinical reporting. Poisson regression analysis accounting for country heterogeneity was computed to estimate first pregnancy incidence post-ART and to identify its associated factors. Pregnancy incidence rate ratios were adjusted on country, baseline CD4 count and clinical stage, hemoglobin, age, first ART regimen, and calendar year. RESULTS: Overall, 29,425 HIV-infectedwomen aged 33 years in median (interquartile range, 28-38) contributed for 84,870 women-years of follow-up to this analysis. The crude incidence of first pregnancy (2304 events) was 2.9 per 100 women-years [95% confidence interval (CI): 2.7 to 3.0], the highest rate being reported among women aged 25-29 years: 4.7 per 100 women-years; 95% CI: 4.3 to 5.1. The overall Kaplan-Meier probability of pregnancy occurrence by the fourth year on ART was 10.9% (95% CI: 10.4 to 11.4) and as high as 28.4% (95% CI: 26.3 to 30.6) among women aged 20-29 years at ART initiation. CONCLUSIONS: The rate of pregnancy occurrence after ART initiation among HIV-infectedwomen living in the West Africa region was high. Family planning services tailored to procreation needs should be provided to all HIV-infectedwomen initiating ART and health consequences carefully monitored in this part of the world.
Authors: Hermann Bussmann; C William Wester; Carolyn N Wester; Bright Lekoko; Okechukwu Okezie; Ann Muir Thomas; S M Victor DeGruttola; Joseph Makhema; Max Essex; Richard G Marlink Journal: J Acquir Immune Defic Syndr Date: 2007-07-01 Impact factor: 3.731
Authors: A J Wilcox; C R Weinberg; J F O'Connor; D D Baird; J P Schlatterer; R E Canfield; E G Armstrong; B C Nisula Journal: N Engl J Med Date: 1988-07-28 Impact factor: 91.245
Authors: Daniel Westreich; Stephen R Cole; Shashi Nagar; Mhairi Maskew; Charles van der Horst; Ian Sanne Journal: PLoS One Date: 2011-08-02 Impact factor: 3.240
Authors: Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones Journal: Contraception Date: 2018-02-09 Impact factor: 3.375
Authors: Katherine B Rucinski; Kimberly A Powers; Sheree R Schwartz; Brian W Pence; Benjamin H Chi; Vivian Black; Helen Rees; Audrey E Pettifor Journal: PLoS One Date: 2018-12-20 Impact factor: 3.240
Authors: Heather C Millar; Alfred K Keter; Beverly S Musick; Edith Apondi; Juddy Wachira; Katherine R MacDonald; Rachel F Spitzer; Paula Braitstein Journal: Reprod Health Date: 2020-12-02 Impact factor: 3.355